Skip to content, Open navigation or Skip to contact information.

Copyright © Inderes 2011 - present. All rights reserved.
Latest
Markets
Stock Comparison
Calendar
Research
Articles
Insider transactions
inderesTV
Portfolio
Forum
About us
Our coverage
Team
Settings
Copyright © Inderes 2011 - present. All rights reserved.

Latest content

Showing All content types
Ascelia Pharma: Update on timeline and funding on Orviglance re-evaluation.
Analyst Comment 14.09.2023 by Henrik Ekman, Claus Thestrup
Ascelia Pharma
Gubra (One-pager): Unique high margin CRO business and a strong obesity portfolio in D&P
Research 08.09.2023 by Henrik Ekman, Philip Coombes, Claus Thestrup
Gubra
Life Science Seminar – Wrap up from our event last week – Thursday the 31st. of August.
Analyst Comment 05.09.2023 by Henrik Ekman, Claus Thestrup
Bavarian NordicBioPortoGubraExpreS2ion Biotech Holding
Gubra stopper samarbejde med Bayer AG.
Analyst Comment 25.08.2023 by Henrik Ekman, Claus Thestrup
Gubra
Egoo Health prepares to enter the US market
Analyst Comment 23.08.2023 by Henrik Ekman, Claus Thestrup
Qlife Holding
Gubra: Peer nyheder på vægttabsmedicin
Analyst Comment 09.08.2023 by Claus Thestrup, Henrik Ekman
Gubra
Qlife - One pager - At-home biomarker and virus testing devices (Egoo System) company.
Research 08.08.2023 by Claus Thestrup, Philip Coombes, Henrik Ekman
Qlife Holding
Hansa Biopharma DMD partner Sarepta wins FDA approval for Elevidys
Analyst Comment 26.06.2023 by Claus Thestrup, Henrik Ekman
Hansa Biopharma
Fireside chat - Pharma Equity Group - One pager
Analyst Comment 15.06.2023 by Claus Thestrup, Henrik Ekman
Pharma Equity Group
Bioporto (One-pager): Diagnostics company with NGAL-test
Research 12.06.2023 by Claus Thestrup, Henrik Ekman, Philip Coombes
BioPorto